Advertisement

Overactive Bladder in Women: an Update for Primary Care Physicians

  • Omar Al Hussein Alawamlh
  • Bashir Al Hussein Al Awamlh
  • Una Lee
  • Richard K. LeeEmail author
Overactive Bladder (U Lee and S Adelstein, Section Editors)
  • 5 Downloads
Part of the following topical collections:
  1. Topical Collection on Overactive Bladder

Abstract

Purpose of Review

Overactive bladder (OAB) is a widely prevalent urinary condition affecting women of all ages, with increasing incidence in advancing age. A primary care provider is likely to encounter a significant proportion of women experiencing lower urinary tract symptoms (LUTS). This review serves primary care physicians as a thorough reference for a common condition causing LUTS in women.

Recent Findings

Most emerging data addressing overactive bladder relates to the different treatment modalities available. The side effect profile of antimuscarinic drugs remains an ongoing concern among OAB patients, especially with recent data linking the use of this class of drugs with Alzheimer’s and future development of dementia. In addition, it was recently demonstrated that individuals taking medications of medium-to-high anticholinergic activity had reduced brain glucose metabolism and increased brain atrophy. Combination treatments seem to be more efficacious than monotherapies, as has been proven when using mirabegron with antimuscarinics. Many studies have also validated the use of neuromodulation as a safe and effective treatment for OAB.

Summary

Overactive bladder is a widely prevalent urinary condition affecting women of all ages. It is regarded as multifactorial with several proposed theories to explain its occurrence. Several tests are available to aid in diagnosing OAB. Symptom severity and patient-related factors including patient preferences drive treatment.

Keywords

Overactive bladder in females Lower urinary tract symptoms Detrusor instability Urinary incontinence 

Notes

Compliance with Ethical Standards

The authors declare that they have no conflict of interest.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009;28(4):287.PubMedCrossRefGoogle Scholar
  2. 2.
    Anger JT, Le TX, Nissim HA, Rogo-Gupta L, Rashid R, Behniwal A, et al. How dry is “OAB-dry”? Perspectives from patients and physician experts. J Urol. 2012;188(5):1811–5.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    The overactive bladder: from basic science to clinical management consensus conference. Proceedings. London, England, June 29, 1997. Urology, 1997 50(6A Suppl): p. 1–114.CrossRefGoogle Scholar
  4. 4.
    Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(6 Suppl 1):2–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.PubMedCrossRefGoogle Scholar
  6. 6.
    Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin. 2007;23(1):65–76.PubMedCrossRefGoogle Scholar
  9. 9.
    Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97(1):96–100.PubMedCrossRefGoogle Scholar
  10. 10.
    Coyne KS, Sexton CC, Thompson C, Kopp ZS, Milsom I, Kaplan SA. The impact of OAB on sexual health in men and women: results from EpiLUTS. J Sex Med. 2011;8(6):1603–15.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Nilsson M, Lalos O, Lindkvist H, Lalos A. How do urinary incontinence and urgency affect women’s sexual life? Acta Obstet Gynecol Scand. 2011;90(6):621–8.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Piancentini A, Stewart WF, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61(6):1123–8.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Hashim H, Abrams P. Overactive bladder: an update. Curr Opin Urol. 2007;17(4):231–6.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Meng E, Lin WY, Lee WC, Chuang YC. Pathophysiology of overactive bladder. Low Urin Tract Symptoms. 2012;4(Suppl 1):48–55.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Palmer CJ, Choi JM. Pathophysiology of overactive bladder: current understanding. Curr Bladder Dysfunct Rep. 2017;12(1):74–9.CrossRefGoogle Scholar
  16. 16.
    Birder L. Role of the urothelium in bladder function. Scand J Urol Nephrol Suppl. 2004;215:48–53.CrossRefGoogle Scholar
  17. 17.
    de Groat WC. The urothelium in overactive bladder: passive bystander or active participant? Urology. 2004;64(6 Suppl 1):7–11.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Meng E, Young JS, Brading AF. Spontaneous activity of mouse detrusor smooth muscle and the effects of the urothelium. Neurourol Urodyn. 2008;27(1):79–87.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Shioyama R, Aoki Y, Ito H, Matsuta Y, Nagase K, Oyama N, et al. Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat. Am J Physiol Regul Integr Comp Physiol. 2008;295(2):R714–8.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Mitchell SA, Brucker BM, Kaefer D, Aponte M, Rosenblum N, Kelly C, et al. Evaluating patients’ symptoms of overactive bladder by questionnaire: the role of urgency in urinary frequency. Urology. 2014;84(5):1039–43.PubMedCrossRefGoogle Scholar
  21. 21.
    de Groat WC, Griffiths D, Yoshimura N. Neural control of the lower urinary tract. Compr Physiol. 2015;5(1):327–96.PubMedPubMedCentralGoogle Scholar
  22. 22.
    De Ridder D, Van Der Aa F, Debruyne J, D’Hooghe B, Dubois MB, Guillaume D, et al. Consensus guidelines on the neurologist’s role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis. Clin Neurol Neurosurg. 2013;115(10):2033–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Laycock J, Jerwood D. Pelvic floor muscle assessment: the PERFECT scheme. Physiotherapy. 2001;87(12):631–42.CrossRefGoogle Scholar
  24. 24.
    Weiss JP, Blaivas JG. Nocturia. 2000;163(1):5–12.Google Scholar
  25. 25.
    Hirayama A, Torimoto K, Yamada A, Tanaka N, Fujimoto K, Yoshida K, et al. Relationship between nocturnal urine volume, leg edema, and urinary antidiuretic hormone in older men. Urology. 2011;77(6):1426–31.PubMedCrossRefGoogle Scholar
  26. 26.
    Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63.PubMedCrossRefGoogle Scholar
  27. 27.
    Moore KH, Simons A, Mukerjee C, Lynch W. The relative incidence of detrusor instability and bacterial cystitis detected on the urodynamic-test day. BJU Int. 2000;85(7):786–92.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Sampselle CM. Behavioral intervention: the first-line treatment for women with urinary incontinence. Curr Urol Rep. 2003;4(5):356–61.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079–86.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn. 2005;24(3):215–25.PubMedCrossRefGoogle Scholar
  31. 31.
    Coyne KS, Sexton CC, Thompson C, Bavendam T, Brubaker L. Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder. Int Urogynecol J. 2015;26(3):373–82.PubMedCrossRefGoogle Scholar
  32. 32.
    Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006;68(2):318–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11(6):563–74.PubMedCrossRefGoogle Scholar
  34. 34.
    Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn. 2003;22(2):105–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Zolnierek KBH, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47(8):826–34.PubMedCrossRefGoogle Scholar
  36. 36.
    Howard F, Steggall M. Urinary incontinence in women: quality of life and help-seeking. Br J Nurs. 2010;19(12):742, 744, 746, 748-9.PubMedCrossRefGoogle Scholar
  37. 37.
    Shamliyan TA, Kane RL, Wyman J, Wilt TJ. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. Ann Intern Med. 2008;148(6):459–73.PubMedCrossRefGoogle Scholar
  38. 38.
    Medicine, I.O. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate, vol. 638. Washington, DC: The National Academies Press; 2005.Google Scholar
  39. 39.
    Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int. 2008;102(1):62–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Lohsiriwat S, Hirunsai M, Chaiyaprasithi B. Effect of caffeine on bladder function in patients with overactive bladder symptoms. Urol Ann. 2011;3(1):14–8.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs. 2002;11(8):560–5.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstet Gynecol. 2000;96(1):85–9.PubMedGoogle Scholar
  43. 43.
    Maserejian NN, Kupelian V, Miyasato G, McVary KT, McKinlay JB. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J Urol. 2012;188(2):490–5.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Dallosso HM, McGrother CW, Matthews RJ, Donaldson MM. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int. 2003;92(1):69–77.PubMedCrossRefGoogle Scholar
  45. 45.
    Bump RC, Sugerman HJ, Fantl JA, McClish DK. Obesity and lower urinary tract function in women: effect of surgically induced weight loss. Am J Obstet Gynecol. 1992;167(2):392–7 discussion 397-9.PubMedCrossRefGoogle Scholar
  46. 46.
    Wing RR, Creasman JM, West DS, Richter HE, Myers D, Burgio KL, et al. Improving urinary incontinence in overweight and obese women through modest weight loss. Obstet Gynecol. 2010;116(2 Pt 1):284–92.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Subak LL, Whitcomb E, Shen H, Saxton J, Vittinghoff E, Brown JS. Weight loss: a novel and effective treatment for urinary incontinence. J Urol. 2005;174(1):190–5.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Wyman JF, Fantl JA. Bladder training in ambulatory care management of urinary incontinence. Urol Nurs. 1991;11(3):11–7.PubMedGoogle Scholar
  49. 49.
    Godec CJ. "Timed voiding"--a useful tool in the treatment of urinary incontinence. Urology. 1984;23(1):97–100.PubMedCrossRefGoogle Scholar
  50. 50.
    Shafik A, Shafik IA. Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol. 2003;20(6):374–7.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Cardozo LD. Biofeedback in overactive bladder. Urology. 2000;55(5A Suppl):24–8 discussion 31-2.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10:Cd005654.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000;48(4):370–4.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011;59(3):377–86.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Iijima K, De Wachter S, Wyndaele JJ. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol. 2007;52(3):842–7.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1997;104(9):988–93.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Homma Y, Paick JS, Lee JG, Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 2003;92(7):741–7.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    •• Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62 This recent case-control study demonstrates the robust association between the use of some anticholinergic medications and the future development of dementia. PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    •• Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33 This study demonstrated the in vivo brain strutural and functional effects of medications with medium-to-high anticholinergic activity. PubMedPubMedCentralGoogle Scholar
  60. 60.
    Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. Bmj. 2018;361:k1315.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Initiative, association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults anticholinergic use, cognition, brain metabolism, and brain atrophy anticholinergic use, cognition, brain metabolism, and brain atrophy. JAMA Neurol. 2016;73(6):721–32.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Suehs BT, Davis C, Franks B, Yuran TE, Ng D, Bradt J, et al. Effect of potentially inappropriate use of antimuscarinic medications on healthcare use and cost in individuals with overactive bladder. J Am Geriatr Soc. 2016;64(4):779–87.PubMedCrossRefGoogle Scholar
  64. 64.
    Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology. 2002;59(5 Suppl 1):25–9.PubMedCrossRefGoogle Scholar
  65. 65.
    •• Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755–65 This recent meta-analysis showed the higher efficiacy of combination therapy: mirabegron and solifenacin. PubMedCrossRefGoogle Scholar
  66. 66.
    Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.PubMedCrossRefGoogle Scholar
  67. 67.
    Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.PubMedCrossRefGoogle Scholar
  68. 68.
    Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–33.PubMedCrossRefGoogle Scholar
  69. 69.
    Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology. 2003;62(4 Suppl 1):45–51.PubMedCrossRefGoogle Scholar
  70. 70.
    Rufford J, Hextall A, Cardozo L, Khullar V. A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(2):78–83.PubMedCrossRefGoogle Scholar
  71. 71.
    Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women--a double-blind placebo-controlled study. J Obstet Gynaecol. 2001;21(4):383–5.PubMedCrossRefGoogle Scholar
  72. 72.
    Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR Jr. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18(9):962–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009;28(1):47–51.PubMedCrossRefGoogle Scholar
  74. 74.
    Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Ebell MH, Radke T, Gardner J. A systematic review of the efficacy and safety of desmopressin for nocturia in adults. J Urol. 2014;192(3):829–35.PubMedCrossRefGoogle Scholar
  76. 76.
    Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.PubMedCrossRefGoogle Scholar
  77. 77.
    •• Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22 This prospective multicenter randomized trial demonstrated that sacral neuromodulation had superior therapeutic success compared with standard medical therapy among refractory patients with mild-to-moderate overactive bladder symptoms. PubMedCrossRefGoogle Scholar
  78. 78.
    •• Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56 This multicenter study shows the durability of sacral neuromodulation as a third-line treatment of overactive bladder on a 3-year follow-up. PubMedCrossRefGoogle Scholar
  79. 79.
    Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93.PubMedCrossRefGoogle Scholar
  80. 80.
    Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Three-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. Urology. 2016;94:57–63.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Adelstein SA, Lee W, Gioia K, Moskowitz D, Stamnes K, Lucioni A, et al. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique. 0(0).Google Scholar
  83. 83.
    Chermansky CJ, Krlin RM, Holley TD, Woo HH, Winters JC. Magnetic resonance imaging following InterStim(R): an institutional experience with imaging safety and patient satisfaction. Neurourol Urodyn. 2011;30(8):1486–8.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Mahran A, Soriano A, Safwat AS, Hijaz A, Mahajan ST, Trabuco EC, et al. The effect of sacral neuromodulation on pregnancy: a systematic review. Int Urogynecol J. 2017;28(9):1357–65.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    de Wall LL, Heesakkers JP. Effectiveness of percutaneous tibial nerve stimulation in the treatment of overactive bladder syndrome. Res Rep Urol. 2017;9:145–57.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–43.PubMedCrossRefGoogle Scholar
  87. 87.
    Finazzi-Agro E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194–201.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Omar Al Hussein Alawamlh
    • 1
  • Bashir Al Hussein Al Awamlh
    • 1
  • Una Lee
    • 2
  • Richard K. Lee
    • 1
    Email author
  1. 1.James Buchanan Brady Foundation, Department of UrologyWeill Cornell Medical College of Cornell UniversityNew YorkUSA
  2. 2.Section of Urology and Renal TransplantationVirginia Mason Medical CenterSeattleUSA

Personalised recommendations